Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 12-28

  Pesonen, Sari ^a,b   Kangasniemi, Lotta ^c   Hemminki, Akseli ^a,b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Oncos Therapeutics Ltd   (Finland)

^d NONE   (Finland)

Author keywords

Cancer; Gene therapy; Oncolytic adenovirus; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CARBOXYLESTERASE; CG 7870; CHLORPROMAZINE; CIDOFOVIR; CISPLATIN; COLOAD1; CONDITIONALLY REPLICATING ADENOVIRUS; CORTICOSTEROID; CV 787; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DOXORUBICIN; ETANERCEPT; FLUCYTOSINE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; H 101; HEAT SHOCK PROTEIN 70; IRINOTECAN; MITOMYCIN C; ONCOLYTIC ADENOVIRUS; ONYX 015; SITIMAGENE CERADENOVEC; THYMIDINE KINASE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ADENOVIRUS 5; ADVANCED CANCER; BREAST TUMOR; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CD4+ T LYMPHOCYTE; CELL DEATH; COLORECTAL CANCER; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; LUNG METASTASIS; LUNG TUMOR; MESENCHYMAL STEM CELL; MULTIMODALITY CANCER THERAPY; NEURAL STEM CELL; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SUICIDE GENE THERAPY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADENOVIRIDAE; GENE THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 79952945559     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100219n     Document Type: Review

References (215)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancerstatistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Nemunaitis, J. Live viruses in cancer treatment. Oncology(Williston Park) 2002, 16, 14831492, discussion 1495-1487.
3. Yu, W.; Fang, H. Clinical trials with oncolytic adenovirus inChina. Curr. Cancer Drug Targets 2007, 7, 141-148. (Pubitemid 46348628)
4. Alemany, R. Cancer selective adenoviruses. Mol. Aspects Med.2007, 28, 42-58.
5. Lin, E.; Nemunaitis, J. Oncolytic viral therapies. Cancer GeneTher. 2004, 11, 643-664. (Pubitemid 39299206)
6. Bauerschmitz, G. J.; Barker, S. D.; Hemminki, A. Adenoviralgene therapy for cancer: from vectors to targeted and replication competent agents (review). Int. J. Oncol. 2002, 21, 1161-1174.
7. Van Dyke, T. A. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 1994, 5,47-60. (Pubitemid 124006635)
8. Small, E. J.; Carducci, M. A.; Burke, J. M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D. C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870,a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 2006, 14, 107-117. (Pubitemid 43899483)
9. Qiao, J.; Kottke, T.; Willmon, C.; Galivo, F.; Wongthida, P.; Diaz, R. M.; Thompson, J.; Ryno, P.; Barber, G. N.; Chester, J.; Selby, P.; Harrington, K.; Melcher, A.; Vile, R. G. Purging metastases in lymphoid organs using a combination of antigennonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 2008, 14, 37-44.
10. Alemany, R.; Cascallo, M. Oncolytic viruses from the perspective of the immune system. Future Microbiol. 2009, 4, 527-536.
11. Di Paolo, N. C.; Tuve, S.; Ni, S.; Hellstrom, K. E.; Hellstrom, I.; Lieber, A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. 2006, 66, 960-969. (Pubitemid 43165964)
12. Prestwich, R. J.; Ilett, E. J.; Errington, F.; Diaz, R. M.; Steele, L. P.; Kottke, T.; Thompson, J.; Galivo, F.; Harrington, K. J.;Pandha, H. S.; Selby, P. J.; Vile, R. G.; Melcher, A. A. Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. Clin. Cancer Res. 2009, 15, 4374-4381.
13. Yu, D. C.; Chen, Y.; Dilley, J.; Li, Y.; Embry, M.; Zhang, H.; Nguyen, N.; Amin, P.; Oh, J.; Henderson, D. R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001, 61, 517-525. (Pubitemid 32128610)
14. Edelstein, M. L.; Abedi, M. R.; Wixon, J. Gene therapy clinicaltrials worldwide to 2007-an update. J. Gene Med. 2007, 9, 833-842. (Pubitemid 47543250)
15. Breidenbach, M.; Rein, D. T.; Wang, M.; Nettelbeck, D. M.; Hemminki, A.; Ulasov, I.; Rivera, A. R.; Everts, M.; Alvarez,R. D.; Douglas, J. T.; Curiel, D. T. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum. Gene Ther. 2004, 15, 509-518. (Pubitemid 38639621)
16. Rein, D. T.; Breidenbach, M.; Wu, H.; Han, T.; Haviv, Y. S.; Wang, M.; Kirby, T. O.; Kawakami, Y.; Dall, P.; Alvarez, R. D.;Curiel, D. T. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int. J. Cancer 2004, 111, 698-704. (Pubitemid 39062891)
17. Cripe, T. P.; Dunphy, E. J.; Holub, A. D.; Saini, A.; Vasi, N. H.; Mahller, Y. Y.; Collins, M. H.; Snyder, J. D.; Krasnykh, V.;Curiel, D. T.; Wickham, T. J.; DeGregori, J.; Bergelson, J. M.;Currier, M. A. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus- adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001, 61, 2953-2960. (Pubitemid 32691940)
18. Li, Y.; Pong, R. C.; Bergelson, J. M.; Hall, M. C.; Sagalowsky, A. I.; Tseng, C. P.; Wang, Z.; Hsieh, J. T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999, 59,325-330. (Pubitemid 29048862)
19. Miller, C. R.; Buchsbaum, D. J.; Reynolds, P. N.; Douglas, J. T.; Gillespie, G. Y.; Mayo, M. S.; Raben, D.; Curiel, D. T. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent genetransfer. Cancer Res. 1998, 58, 5738-5748. (Pubitemid 29006415)
20. Hemmi, S.; Geertsen, R.; Mezzacasa, A.; Peter, I.; Dummer, R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther.1998, 9, 2363-2373. (Pubitemid 28523985)
21. Glasgow, J. N.; Everts, M.; Curiel, D. T. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006,13, 830-844.
22. Campos, S. K.; Barry, M. A. Current advances and future challenges in adenoviral vector biology and targeting. Curr.Gene Ther. 2007, 7, 189-204. (Pubitemid 46902201)
23. Hemminki, A.; Kanerva, A.; Liu, B.; Wang, M.; Alvarez, R. D.; Siegal, G. P.; Curiel, D. T. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.Cancer Res. 2003, 63, 847-853. (Pubitemid 36231986)
24. Goldsmith, M. E.; Kitazono, M.; Fok, P.; Aikou, T.; Bates, S.; Fojo, T. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.Clin. Cancer Res. 2003, 9, 5394-5401. (Pubitemid 37413595)
25. Kitazono, M.; Goldsmith, M. E.; Aikou, T.; Bates, S.; Fojo, T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 2001, 61, 6328-6330. (Pubitemid 32783231)
26. Bieler, A.; Mantwill, K.; Dravits, T.; Bernshausen, A.; Glockzin, G.; Kohler-Vargas, N.; Lage, H.; Gansbacher, B.; Holm, P. S. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum. Gene Ther. 2006,17, 55-70. (Pubitemid 43100515)
27. Guse, K.; Ranki, T.; Ala-Opas, M.; Bono, P.; Sarkioja, M.; Rajecki, M.; Kanerva, A.; Hakkarainen, T.; Hemminki, A. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol. Cancer Ther. 2007, 6, 2728-2736. (Pubitemid 350058153)
28. Sarkioja, M.; Pesonen, S.; Raki, M.; Hakkarainen, T.; Salo, J.; Ahonen, M. T.; Kanerva, A.; Hemminki, A. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther. 2008, 15, 921-929. (Pubitemid 351791479)
29. Kangasniemi, L.; Kiviluoto, T.; Kanerva, A.; Raki, M.; Ranki,T.; Sarkioja, M.; Wu, H.; Marini, F.; Hockerstedt, K.; Isoniemi, H.; Alfthan, H.; Stenman, U. H.; Curiel, D. T.; Hemminki, A. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin. Cancer Res. 2006, 12, 3137-3144. (Pubitemid 43837362)
30. Grzesiak, J. J.; Ho, J. C.; Moossa, A. R.; Bouvet, M. The integrinextracellular matrix axis in pancreatic cancer. Pancreas 2007,35, 293-301. (Pubitemid 350307370)
31. Kawashima, A.; Tsugawa, S.; Boku, A.; Kobayashi, M.; Minamoto, T.; Nakanishi, I.; Oda, Y. Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol. Res. Pract. 2003, 199, 57-64. (Pubitemid 36519495)
32. Marshall, J. F.; Hart, I. R. The role of alpha v-integrins in tumour progression and metastasis. Semin. Cancer Biol. 1996, 7, 129-138. (Pubitemid 26179260)
33. Theocharis, A. D.; Vynios, D. H.; Papageorgakopoulou, N.; Skandalis, S. S.; Theocharis, D. A. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int. J. Biochem. Cell Biol. 2003, 35, 376-390. (Pubitemid 36084460)
34. Kleeff, J.; Ishiwata, T.; Kumbasar, A.; Friess, H.; Buchler, M. W.; Lander, A. D.; Korc, M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in humanpan creatic cancer. J. Clin. InVest. 1998, 102, 1662-1673. (Pubitemid 28516251)
35. Matsuda, K.; Maruyama, H.; Guo, F.; Kleeff, J.; Itakura, J.; Matsumoto, Y.; Lander, A. D.; Korc, M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61, 5562-5569. (Pubitemid 32694943)
36. Barbareschi, M.; Maisonneuve, P.; Aldovini, D.; Cangi, M. G.; Pecciarini, L.; Angelo Mauri, F.; Veronese, S.; Caffo, O.;Lucenti, A.; Palma, P. D.; Galligioni, E.; Doglioni, C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98,474-483. (Pubitemid 36885986)
37. Burbach, B. J.; Friedl, A.; Mundhenke, C.; Rapraeger, A. C. Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol. 2003, 22, 163-177. (Pubitemid 36627474)
38. Burbach, B. J.; Ji, Y.; Rapraeger, A. C. Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinomacells. Exp. Cell Res. 2004, 300, 234-247. (Pubitemid 39286232)
39. Eriksson, M.; Guse, K.; Bauerschmitz, G.; Virkkunen, P.; Tarkkanen, M.; Tanner, M.; Hakkarainen, T.; Kanerva, A.; Desmond, R. A.; Pesonen, S.; Hemminki, A. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.Mol. Ther. 2007, 15, 2088-2093. (Pubitemid 350148923)
40. Ranki, T.; Kanerva, A.; Ristimaki, A.; Hakkarainen, T.; Sarkioja,M.; Kangasniemi, L.; Raki, M.; Laakkonen, P.; Goodison, S.; Hemminki, A. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther. 2007, 14, 58-67. (Pubitemid 44942866)
41. Krasnykh, V. N.; Mikheeva, G. V.; Douglas, J. T.; Curiel, D. T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 1996, 70, 6839-6846. (Pubitemid 26307395)
42. Kanerva, A.; Mikheeva, G. V.; Krasnykh, V.; Coolidge, C. J.;Lam, J. T.; Mahasreshti, P. J.; Barker, S. D.; Straughn, M.; Barnes, M. N.; Alvarez, R. D.; Hemminki, A.; Curiel, D. T.Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res.2002, 8, 275-280. (Pubitemid 34101488)
43. Tuve, S.; Wang, H.; Jacobs, J. D.; Yumul, R. C.; Smith, D. F.; Lieber, A. Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog.2008, 4, e1000189.
44. Volk, A. L.; Rivera, A. A.; Kanerva, A.; Bauerschmitz, G.; Dmitriev, I.; Nettelbeck, D. M.; Curiel, D. T. Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol. Ther.2003, 2, 511-515.
45. Ramirez, P. J.; Vickers, S. M.; Ono, H. A.; Davydova, J.; Takayama, K.; Thompson, T. C.; Curiel, D. T.; Bland, K. I.; Yamamoto, M. Optimization of conditionally replicative adenovirusfor pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am. J. Surg. 2008, 195, 481-490. (Pubitemid 351417474)
46. Hoffmann, D.; Bayer, W.; Heim, A.; Potthoff, A.; Nettelbeck, D. M.; Wildner, O. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J. InVest. Dermatol. 2008, 128, 988-998. (Pubitemid 351374310)
47. Zhu, Z. B.; Mathis, J. M.; Makhija, S. K.; Lu, B.; Wang, M.; Ji, S.; Rivera, A. A.; Rosenthal, E. L.; Siegal, G. P.; Curiel, D. T. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Int. J.Oncol. 2007, 31, 1213-1222.
48. Ulasov, I. V.; Rivera, A. A.; Han, Y.; Curiel, D. T.; Zhu, Z. B.; Lesniak, M. S. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J. Neurosurg. 2007, 107, 617-627. (Pubitemid 47451047)
49. Gaggar, A.; Shayakhmetov, D. M.; Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003, 9, 1408-1412. (Pubitemid 37466191)
50. Kinugasa, N.; Higashi, T.; Nouso, K.; Nakatsukasa, H.; Kobayashi, Y.; Ishizaki, M.; Toshikuni, N.; Yoshida, K.; Uematsu, S.; Tsuji, T. Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br. J. Cancer 1999, 80, 1820-1825. (Pubitemid 29389639)
51. Murray, K. P.; Mathure, S.; Kaul, R.; Khan, S.; Carson, L. F.; Twiggs, L. B.; Martens, M. G.; Kaul, A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol. Oncol.2000, 76, 176-182. (Pubitemid 30067192)
52. Fishelson, Z.; Donin, N.; Zell, S.; Schultz, S.; Kirschfink, M.Obstacles to cancer immunotherapy: expression of membranecomplement regulatory proteins (mCRPs) in tumors. Mol.Immunol. 2003, 40, 109-123. (Pubitemid 36959821)
53. Liu, Y.; Wang, H.; Yumul, R.; Gao, W.; Gambotto, A.; Morita,T.; Baker, A.; Lieber, A. Transduction of liver metastases afterintravenous injection of Ad5/35 or Ad35 vectors with and withoutfactor X-binding protein pretreatment. Hum. Gene Ther. 2009,20, 621-629.
54. Wang, G.; Li, G.; Liu, H.; Yang, C.; Yang, X.; Jin, J.; Liu, X.;Qian, Q.; Qian, W. E1B 55-kDa deleted, Ad5/F35 fiber chimericadenovirus, a potential oncolytic agent for B-lymphocyticmalignancies. J. Gene Med. 2009, 11, 477-485.
55. Kuhn, I.; Harden, P.; Bauzon, M.; Chartier, C.; Nye, J.; Thorne,S.; Reid, T.; Ni, S.; Lieber, A.; Fisher, K.; Seymour, L.; Rubanyi,G. M.; Harkins, R. N.; Hermiston, T. W. Directed evolutiongenerates a novel oncolytic virus for the treatment of coloncancer. PLoS One 2008, 3, e2409.
56. Korn, T.; Nettelbeck, D. M.; Volkel, T.; Muller, R.; Kontermann,R. E. Recombinant bispecific antibodies for the targeting ofadenoviruses to CEA-expressing tumour cells: a comparativeanalysis of bacterially expressed single-chain diabody and tandemscFv. J. Gene Med. 2004, 6, 642-651. (Pubitemid 40228080)
57. Douglas, J. T.; Rogers, B. E.; Rosenfeld, M. E.; Michael, S. I.;Feng, M.; Curiel, D. T. Targeted gene delivery by tropismmodifiedadenoviral vectors. Nat. Biotechnol. 1996, 14, 1574-1578. (Pubitemid 26365552)
58. Reynolds, P. N.; Zinn, K. R.; Gavrilyuk, V. D.; Balyasnikova,I. V.; Rogers, B. E.; Buchsbaum, D. J.; Wang, M. H.; Miletich,D. J.; Grizzle, W. E.; Douglas, J. T.; Danilov, S. M.; Curiel,D. T. A targetable, injectable adenoviral vector for selective genedelivery to pulmonary endothelium in vivo. Mol. Ther. 2000, 2,562-578.
59. Curiel, D. T.; Douglas, J. T. Adenoviral Vectors for gene therapy; Elsevier: 2002.
60. Hemminki, A.; Dmitriev, I.; Liu, B.; Desmond, R. A.; Alemany,R.; Curiel, D. T. Targeting oncolytic adenoviral agents to theepidermal growth factor pathway with a secretory fusionmolecule. Cancer Res. 2001, 61, 6377-6381. (Pubitemid 32783241)
61. Worgall, S.; Wolff, G.; Falck-Pedersen, E.; Crystal, R. G. Innateimmune mechanisms dominate elimination of adenoviral vectorsfollowing in vivo administration. Hum. Gene Ther. 1997, 8, 37-44. (Pubitemid 27075341)
62. Alemany, R.; Suzuki, K.; Curiel, D. T. Blood clearance rates ofadenovirus type 5 in mice. J. Gen. Virol. 2000, 81, 2605-2609.
63. Xu, Z.; Tian, J.; Smith, J. S.; Byrnes, A. P. Clearance ofadenovirus by Kupffer cells is mediated by scavenger receptors,natural antibodies, and complement. J. Virol. 2008, 82, 11705-11713.
64. Alemany, R.; Curiel, D. T. CAR-binding ablation does not changebiodistribution and toxicity of adenoviral vectors. Gene Ther.2001, 8, 1347-1353. (Pubitemid 32834304)
65. Shayakhmetov, D. M.; Gaggar, A.; Ni, S.; Li, Z. Y.; Lieber, A.Adenovirus binding to blood factors results in liver cell infectionand hepatotoxicity. J. Virol. 2005, 79, 7478-7491. (Pubitemid 40756784)
66. Kalyuzhniy, O.; Di Paolo, N. C.; Silvestry, M.; Hofherr, S. E.;Barry, M. A.; Stewart, P. L.; Shayakhmetov, D. M. Adenovirusserotype 5 hexon is critical for virus infection of hepatocytes invivo. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5483-5488. (Pubitemid 351753889)
67. Waddington, S. N.; McVey, J. H.; Bhella, D.; Parker, A. L.;Barker, K.; Atoda, H.; Pink, R.; Buckley, S. M.; Greig, J. A.;Denby, L.; Custers, J.; Morita, T.; Francischetti, I. M.; Monteiro,R. Q.; Barouch, D. H.; van Rooijen, N.; Napoli, C.; Havenga,M. J.; Nicklin, S. A.; Baker, A. H. Adenovirus serotype 5 hexonmediates liver gene transfer. Cell 2008, 132, 397-409. (Pubitemid 351200513)
68. Parker, A. L.; Waddington, S. N.; Nicol, C. G.; Shayakhmetov,D. M.; Buckley, S. M.; Denby, L.; Kemball-Cook, G.; Ni, S.;Lieber, A.; McVey, J. H.; Nicklin, S. A.; Baker, A. H. Multiplevitamin K-dependent coagulation zymogens promote adenovirusmediatedgene delivery to hepatocytes. Blood 2006, 108, 2554-2561.
69. Koski, A.; Rajecki, M.; Guse, K.; Kanerva, A.; Ristimaki, A.;Pesonen, S.; Escutenaire, S.; Hemminki, A. Systemic adenoviralgene delivery to orthotopic murine breast tumors with ablationof coagulation factors, thrombocytes and Kupffer cells. J. GeneMed. 2009, 11, 966-977.
70. Quintanar-Guerrero, D.; Ganem-Quintanar, A.; Nava-Arzaluz,M. G.; Pinon-Segundo, E. Silica xerogels as pharmaceutical drugcarriers. Expert Opin. Drug Delivery 2009, 6, 485-498.
71. Kangasniemi, L.; Koskinen, M.; Jokinen, M.; Toriseva, M.; Ala-Aho, R.; Kahari, V. M.; Jalonen, H.; Yla-Herttuala, S.; Moilanen,H.; Stenman, U. H.; Diaconu, I.; Kanerva, A.; Pesonen, S.;Hakkarainen, T.; Hemminki, A. Extended release of adenovirusfrom silica implants in vitro and in vivo. Gene Ther. 2009, 16,103-110.
72. Freytag, S. O.; Stricker, H.; Pegg, J.; Paielli, D.; Pradhan, D. G.;Peabody, J.; DePeralta-Venturina, M.; Xia, X.; Brown, S.; Lu,M.; Kim, J. H. Phase I study of replication-competent adenovirusmediateddouble-suicide gene therapy in combination withconventional-dose three-dimensional conformal radiation therapyfor the treatment of newly diagnosed, intermediate- to high-riskprostate cancer. Cancer Res. 2003, 63, 7497-7506. (Pubitemid 37413494)
73. Feng, B.; Chen, L. Review of mesenchymal stem cells andtumors: executioner or coconspirator. Cancer Biother. Radiopharm.2009, 24, 717-721.
74. Hakkarainen, T.; Sarkioja, M.; Lehenkari, P.; Miettinen, S.;Ylikomi, T.; Suuronen, R.; Desmond, R. A.; Kanerva, A.;Hemminki, A. Human mesenchymal stem cells lack tumortropism but enhance the antitumor activity of oncolytic adenovirusesin orthotopic lung and breast tumors. Hum. Gene Ther.2007, 18, 627-641. (Pubitemid 47187094)
75. Garcia-Castro, J.; Alemany, R.; Cascallo, M.; Martinez-Quintanilla,J.; Del Mar Arriero, M.; Lassaletta, A.; Madero, L.;Ramirez, M. Treatment of metastatic neuroblastoma withsystemic oncolytic virotherapy delivered by autologous mesenchymalstem cells: an exploratory study. Cancer Gene Ther.2010, 17, 476-483.
76. Tyler, M. A.; Ulasov, I. V.; Sonabend, A. M.; Nandi, S.; Han,Y.; Marler, S.; Roth, J.; Lesniak, M. S. Neural stem cells targetintracranial glioma to deliver an oncolytic adenovirus in vivo.Gene Ther. 2009, 16, 262-278.
77. Garcia-Castro, J.; Martinez-Palacio, J.; Lillo, R.; Garcia-Sanchez,F.; Alemany, R.; Madero, L.; Bueren, J. A.; Ramirez, M. Tumorcells as cellular vehicles to deliver gene therapies to metastatictumors. Cancer Gene Ther. 2005, 12, 341-349. (Pubitemid 40411193)
78. Saukkonen, K.; Hemminki, A. Tissue-specific promoters forcancer gene therapy. Expert Opin. Biol. Ther. 2004, 4, 683-696. (Pubitemid 38667814)
79. Nettelbeck, D. M. Cellular genetic tools to control oncolyticadenoviruses for virotherapy of cancer. J. Mol. Med. 2008, 86,363-377.
80. Rodriguez, R.; Schuur, E. R.; Lim, H. Y.; Henderson, G. A.;Simons, J. W.; Henderson, D. R. Prostate attenuated replicationcompetent adenovirus (ARCA) CN706: a selective cytotoxic forprostate-specific antigen-positive prostate cancer cells. CancerRes. 1997, 57, 2559-2563. (Pubitemid 27283756)
81. Li, Y.; Chen, Y.; Dilley, J.; Arroyo, T.; Ko, D.; Working, P.;Yu, D. C. Carcinoembryonic antigen-producing cell-specificoncolytic adenovirus, OV798, for colorectal cancer therapy. Mol.Cancer Ther. 2003, 2, 1003-1009.
82. Li, Y.; Yu, D. C.; Chen, Y.; Amin, P.; Zhang, H.; Nguyen, N.;Henderson, D. R. A hepatocellular carcinoma-specific adenovirusvariant, CV890, eliminates distant human liver tumors incombination with doxorubicin. Cancer Res. 2001, 61, 6428-6436. (Pubitemid 32783248)
83. Nettelbeck, D. M.; Rivera, A. A.; Balague, C.; Alemany, R.;Curiel, D. T. Novel oncolytic adenoviruses targeted to melanoma:specific viral replication and cytolysis by expression of E1Amutants from the tyrosinase enhancer/promoter. Cancer Res.2002, 62, 4663-4670.
84. Peter, I.; Graf, C.; Dummer, R.; Schaffner, W.; Greber, U. F.;Hemmi, S. A novel attenuated replication-competent adenovirusfor melanoma therapy. Gene Ther. 2003, 10, 530-539. (Pubitemid 36432604)
85. Bauerschmitz, G. J.; Ranki, T.; Kangasniemi, L.; Ribacka, C.;Eriksson, M.; Porten, M.; Herrmann, I.; Ristimaki, A.; Virkkunen,P.; Tarkkanen, M.; Hakkarainen, T.; Kanerva, A.; Rein, D.;Pesonen, S.; Hemminki, A. Tissue-specific promoters active inCD44+CD24-/low breast cancer cells. Cancer Res. 2008, 68,5533-5539.
86. Bauerschmitz, G. J.; Guse, K.; Kanerva, A.; Menzel, A.;Herrmann, I.; Desmond, R. A.; Yamamoto, M.; Nettelbeck,D. M.; Hakkarainen, T.; Dall, P.; Curiel, D. T.; Hemminki, A.Triple-targeted oncolytic adenoviruses featuring the cox2 promoter,E1A transcomplementation, and serotype chimerism forenhanced selectivity for ovarian cancer cells. Mol. Ther. 2006,14, 164-174. (Pubitemid 43964496)
87. Yamamoto, M.; Davydova, J.; Wang, M.; Siegal, G. P.;Krasnykh, V.; Vickers, S. M.; Curiel, D. T. Infectivity enhanced,cyclooxygenase-2 promoter-based conditionally replicative adenovirusfor pancreatic cancer. Gastroenterology 2003, 125,1203-1218. (Pubitemid 37193465)
88. Li, X.; Zhang, Y. P.; Kim, H. S.; Bae, K. H.; Stantz, K. M.;Lee, S. J.; Jung, C.; Jimenez, J. A.; Gardner, T. A.; Jeng, M. H.;Kao, C. Gene therapy for prostate cancer by controllingadenovirus E1a and E4 gene expression with PSES enhancer.Cancer Res. 2005, 65, 1941-1951. (Pubitemid 40478624)
89. Heise, C.; Hermiston, T.; Johnson, L.; Brooks, G.; Sampson-Johannes, A.; Williams, A.; Hawkins, L.; Kirn, D. An adenovirusE1A mutant that demonstrates potent and selective systemic antitumoralefficacy. Nat. Med. 2000, 6, 1134-1139.
90. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P. S.;McDonnell, T. J.; Mitlianga, P.; Shi, Y. X.; Levin, V. A.; Yung,W. K.; Kyritsis, A. P. A mutant oncolytic adenovirus targetingthe Rb pathway produces anti-glioma effect in vivo. Oncogene2000, 19, 2-12.
91. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
92. Hernando, E.; Nahle, Z.; Juan, G.; Diaz-Rodriguez, E.; Alaminos,M.; Hemann, M.; Michel, L.; Mittal, V.; Gerald, W.; Benezra,R.; Lowe, S. W.; Cordon-Cardo, C. Rb inactivation promotesgenomic instability by uncoupling cell cycle progression frommitotic control. Nature 2004, 430, 797-802. (Pubitemid 39071352)
93. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.;Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey,A.; McCormick, F. An adenovirus mutant that replicatesselectively in p53-deficient human tumor cells. Science 1996,274, 373-376. (Pubitemid 26353341)
94. Harada, J. N.; Berk, A. J. p53-Independent and -dependentrequirements for E1B-55K in adenovirus type 5 replication.J. Virol. 1999, 73, 5333-5344. (Pubitemid 29274815)
95. Dix, B. R.; Edwards, S. J.; Braithwaite, A. W. Does the antitumoradenovirus ONYX-015/dl1520 selectively target cells defectivein the p53 pathway. J. Virol. 2001, 75, 5443-5447. (Pubitemid 32488136)
96. O'Shea, C. C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.;Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen,Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNAexport, rather than p53 inactivation, determines ONYX-015tumor selectivity. Cancer Cell 2004, 6, 611-623. (Pubitemid 40017704)
97. O'Shea, C. C.; Soria, C.; Bagus, B.; McCormick, F. Heat shockphenocopies E1B-55K late functions and selectively sensitizesrefractory tumor cells to ONYX-015 oncolytic viral therapy.Cancer Cell 2005, 8, 61-74. (Pubitemid 40991815)
98. Goodrum, F. D.; Ornelles, D. A. p53 status does not determineoutcome of E1B 55-kilodalton mutant adenovirus lytic infection.J. Virol. 1998, 72, 9479-9490. (Pubitemid 28520811)
99. Cascallo, M.; Gros, A.; Bayo, N.; Serrano, T.; Capella, G.;Alemany, R. Deletion of VAI and VAII RNA genes in the designof oncolytic adenoviruses. Hum. Gene Ther. 2006, 17, 929-940. (Pubitemid 46076753)
100. Perucho, M.; Goldfarb, M.; Shimizu, K.; Lama, C.; Fogh, J.;Wigler, M. Human-tumor-derived cell lines contain common anddifferent transforming genes. Cell 1981, 27, 467-476.
101. Krontiris, T. G.; Cooper, G. M. Transforming activity of humantumor DNAs. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 1181-1184. (Pubitemid 11102184)
102. Shih, C.; Padhy, L. C.; Murray, M.; Weinberg, R. A. Transforminggenes of carcinomas and neuroblastomas introduced intomouse fibroblasts. Nature 1981, 290, 261-264. (Pubitemid 11149660)
103. Garcia-Rostan, G.; Zhao, H.; Camp, R. L.; Pollan, M.; Herrero,A.; Pardo, J.; Wu, R.; Carcangiu, M. L.; Costa, J.; Tallini, G.ras mutations are associated with aggressive tumor phenotypesand poor prognosis in thyroid cancer. J. Clin. Oncol. 2003, 21,3226-3235. (Pubitemid 46606254)
104. Guse, K.; Diaconu, I.; Rajecki, M.; Sloniecka, M.; Hakkarainen,T.; Ristimaki, A.; Kanerva, A.; Pesonen, S.; Hemminki, A. Ad5/3-9HIF-Delta24-VEGFR- 1-Ig, an infectivity enhanced, dualtargetedand antiangiogenic oncolytic adenovirus for kidneycancer treatment. Gene Ther. 2009, 16, 1009-1020.
105. Kuo, C. J.; Farnebo, F.; Yu, E. Y.; Christofferson, R.; Swearingen,R. A.; Carter, R.; von Recum, H. A.; Yuan, J.; Kamihara,J.; Flynn, E.; D'Amato, R.; Folkman, J.; Mulligan, R. C.Comparative evaluation of the antitumor activity of antiangiogenicproteins delivered by gene transfer. Proc. Natl. Acad. Sci.U.S.A. 2001, 98, 4605-4610. (Pubitemid 32295023)
106. Thorne, S. H.; Tam, B. Y.; Kirn, D. H.; Contag, C. H.; Kuo,C. J. Selective intratumoral amplification of an antiangiogenicvector by an oncolytic virus produces enhanced antivascular andanti-tumor efficacy. Mol. Ther. 2006, 13, 938-946.
107. Zhang, Z.; Zou, W.; Wang, J.; Gu, J.; Dang, Y.; Li, B.; Zhao,L.; Qian, C.; Qian, Q.; Liu, X. Suppression of tumor growth byoncolytic adenovirus-mediated delivery of an antiangiogenicgene, soluble Flt-1. Mol. Ther. 2005, 11, 553-562. (Pubitemid 40353113)
108. Kim, J. H.; Lee, Y. S.; Kim, H.; Huang, J. H.; Yoon, A. R.;Yun, C. O. Relaxin expression from tumor-targeting adenovirusesand its intratumoral spread, apoptosis induction, and efficacy.J. Natl. Cancer Inst. 2006, 98, 1482-1493. (Pubitemid 44605593)
109. Guedan, S.; Rojas, J. J.; Gros, A.; Mercade, E.; Cascallo, M.;Alemany, R. Hyaluronidase Expression by an Oncolytic AdenovirusEnhances Its Intratumoral Spread and Suppresses TumorGrowth. Mol. Ther. 2010, 18, 1275-1283.
110. McKee, T. D.; Grandi, P.; Mok, W.; Alexandrakis, G.; Insin,N.; Zimmer, J. P.; Bawendi, M. G.; Boucher, Y.; Breakefield,X. O.; Jain, R. K. Degradation of fibrillar collagen in a humanmelanoma xenograft improves the efficacy of an oncolytic herpessimplex virus vector. Cancer Res. 2006, 66, 2509-2513.
111. Mok, W.; Boucher, Y.; Jain, R. K. Matrix metalloproteinases-1and-8 improve the distribution and efficacy of an oncolyticvirus. Cancer Res. 2007, 67, 10664-10668. (Pubitemid 350145891)
112. Raki, M.; Hakkarainen, T.; Bauerschmitz, G. J.; Sarkioja, M.;Desmond, R. A.; Kanerva, A.; Hemminki, A. Utility of TK/GCV in the context of highly effective oncolysis mediated by aserotype 3 receptor targeted oncolytic adenovirus. Gene Ther.2007, 14, 1380-1388. (Pubitemid 47423737)
113. Dias, J. D.; Liikanen, I.; Guse, K.; Foloppe, J.; Sloniecka, M.;Diaconu, I.; Rantanen, V.; Eriksson, M.; Hakkarainen, T.; Lusky,M.; Erbs, P.; Escutenaire, S.; Kanerva, A.; Pesonen, S.; Cerullo,V.; Hemminki, A. Targeted chemotherapy for head and neckcancer with a chimeric oncolytic adenovirus coding for bifunctionalsuicide protein FCU1. Clin. Cancer Res. 2010, 16, 2540-2549.
114. Rogulski, K. R.; Wing, M. S.; Paielli, D. L.; Gilbert, J. D.; Kim,J. H.; Freytag, S. O. Double suicide gene therapy augments theantitumor activity of a replication-competent lytic adenovirusthrough enhanced cytotoxicity and radiosensitization. Hum. GeneTher. 2000, 11, 67-76. (Pubitemid 30044041)
115. Freytag, S. O.; Paielli, D.; Wing, M.; Rogulski, K.; Brown, S.;Kolozsvary, A.; Seely, J.; Barton, K.; Dragovic, A.; Kim, J. H.Efficacy and toxicity of replication-competent adenovirusmediateddouble suicide gene therapy in combination withradiation therapy in an orthotopic mouse prostate cancer model.Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 873-885.
116. Oosterhoff, D.; Pinedo, H. M.; Witlox, M. A.; Carette, J. E.;Gerritsen, W. R.; van Beusechem, V. W. Gene-directed enzymeprodrug therapy with carboxylesterase enhances the anticancerefficacy of the conditionally replicating adenovirus AdDelta24.Gene Ther. 2005, 12, 1011-1018. (Pubitemid 40903423)
117. Park, B. H.; Hwang, T.; Liu, T. C.; Sze, D. Y.; Kim, J. S.; Kwon,H. C.; Oh, S. Y.; Han, S. Y.; Yoon, J. H.; Hong, S. H.; Moon,A.; Speth, K.; Park, C.; Ahn, Y. J.; Daneshmand, M.; Rhee,B. G.; Pinedo, H. M.; Bell, J. C.; Kirn, D. H. Use of a targetedoncolytic poxvirus, JX-594, in patients with refractory primaryor metastatic liver cancer: a phase I trial. Lancet Oncol. 2008,9, 533-542.
118. Senzer, N. N.; Kaufman, H. L.; Amatruda, T.; Nemunaitis, M.;Reid, T.; Daniels, G.; Gonzalez, R.; Glaspy, J.; Whitman, E.;Harrington, K.; Goldsweig, H.; Marshall, T.; Love, C.; Coffin,R.; Nemunaitis, J. J. Phase II clinical trial of a granulocytemacrophagecolony-stimulating factor-encoding, second-generationoncolytic herpesvirus in patients with unresectable metastaticmelanoma. J. Clin. Oncol. 2009, 27, 5763-5771.
119. Hu, J. C.; Coffin, R. S.; Davis, C. J.; Graham, N. J.; Groves, N.;Guest, P. J.; Harrington, K. J.; James, N. D.; Love, C. A.;McNeish, I.; Medley, L. C.; Michael, A.; Nutting, C. M.; Pandha,H. S.; Shorrock, C. A.; Simpson, J.; Steiner, J.; Steven, N. M.;Wright, D.; Coombes, R. C. A phase I study of OncoVEXGMCSF,a second-generation oncolytic herpes simplex virus expressinggranulocyte macrophage colony-stimulating factor. Clin.Cancer Res. 2006, 12, 6737-6747. (Pubitemid 44876843)
120. Chang, J.; Zhao, X.; Wu, X.; Guo, Y.; Guo, H.; Cao, J.; Lou,D.; Yu, D.; Li, J. A Phase I study of KH901, a conditionallyreplicating granulocyte- macrophage colony-stimulating factor:armed oncolytic adenovirus for the treatment of head and neckcancers. Cancer Biol. Ther. 2009, 8, 676-682.
121. Cerullo, V.; Pesonen, S.; Diaconu, I.; Escutenaire, S.; Arstila,P. T.; Ugolini, M.; Nokisalmi, P.; Raki, M.; Laasonen, L.;Sarkioja, M.; Rajecki, M.; Kangasniemi, L.; Guse, K.; Helminen,A.; Ahtiainen, L.; Ristimaki, A.; Raisanen-Sokolowski, A.;Haavisto, E.; Oksanen, M.; Karli, E.; Karioja-Kallio, A.; Holm,S. L.; Kouri, M.; Joensuu, T.; Kanerva, A.; Hemminki, A.Oncolytic adenovirus coding for Granulocyte macrophage colonystimulatingfactor (GMCSF) induces anti-tumoral immunity inhuman cancer patients. Cancer Res. 2010, 70, 4297-4309.
122. Merrick, A. E.; Ilett, E. J.; Melcher, A. A. JX-594, a targetedoncolytic poxvirus for the treatment of cancer. Curr. Opin. InVest.Drugs 2009, 10, 1372-1382.
123. Prestwich, R. J.; Errington, F.; Diaz, R. M.; Pandha, H. S.;Harrington, K. J.; Melcher, A. A.; Vile, R. G. The case ofoncolytic viruses versus the immune system: waiting on thejudgment of Solomon. Hum. Gene Ther. 2009, 20, 1119-1132.
124. Muruve, D. A. The innate immune response to adenovirusvectors. Hum. Gene Ther. 2004, 15, 1157-1166. (Pubitemid 40052429)
125. Lenaerts, L.; De Clercq, E.; Naesens, L. Clinical features andtreatment of adenovirus infections. ReV. Med. Virol. 2008, 18,357-374.
126. Dhar, D.; Spencer, J. F.; Toth, K.; Wold, W. S. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 2009, 83, 2130-2139.
127. Dhar, D.; Spencer, J. F.; Toth, K.; Wold, W. S. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol. Ther. 2009, 17, 1724-1732.
128. Prestwich, R. J.; Harrington, K. J.; Pandha, H. S.; Vile, R. G.; Melcher, A. A.; Errington, F. Oncolytic viruses: a novel form of immunotherapy. Expert ReV. Anticancer Ther. 2008, 8, 1581-1588.
129. Tuve, S.; Liu, Y.; Tragoolpua, K.; Jacobs, J. D.; Yumul, R. C.; Li, Z. Y.; Strauss, R.; Hellstrom, K. E.; Disis, M. L.; Roffler, S.; Lieber, A. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009, 27, 4225-4239.
130. Raper, S. E.; Chirmule, N.; Lee, F. S.; Wivel, N. A.; Bagg, A.; Gao, G. P.; Wilson, J. M.; Batshaw, M. L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80, 148-158. (Pubitemid 37272241)
131. Guse, K.; Hemminki, A. Cancer gene therapy with oncolytic adenoviruses. J. BUON 2009, 14 (Suppl. 1), S7-15.
132. Gall, J. G.; Crystal, R. G.; Falck-Pedersen, E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 1998, 72, 10260-10264. (Pubitemid 28520902)
133. Roy, S.; Shirley, P. S.; McClelland, A.; Kaleko, M. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 1998, 72, 6875-6879. (Pubitemid 28324008)
134. Rux, J. J.; Burnett, R. M. Adenovirus structure. Hum. Gene Ther. 2004, 15, 1167-1176. (Pubitemid 40052430)
135. Wohlfart, C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 1988, 62, 2321-2328.
136. Wu, H.; Dmitriev, I.; Kashentseva, E.; Seki, T.; Wang, M.; Curiel, D. T. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 2002, 76, 12775-12782. (Pubitemid 35386961)
137. Molinier-Frenkel, V.; Lengagne, R.; Gaden, F.; Hong, S. S.; Choppin, J.; Gahery-Segard, H.; Boulanger, P.; Guillet, J. G. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 2002, 76, 127-135. (Pubitemid 33138998)
138. Engelhardt, J. F.; Simon, R. H.; Yang, Y.; Zepeda, M.; Weber- Pendleton, S.; Doranz, B.; Grossman, M.; Wilson, J. M. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum. Gene Ther. 1993, 4, 759-769. (Pubitemid 24305770)
139. Kozarsky, K. F.; McKinley, D. R.; Austin, L. L.; Raper, S. E.; Stratford-Perricaudet, L. D.; Wilson, J. M. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 1994, 269, 13695-13702. (Pubitemid 24206152)
140. Yang, Y.; Nunes, F. A.; Berencsi, K.; Furth, E. E.; Gonczol, E.; Wilson, J. M. Cellular immunity to viral antigens limits E1- deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4407-4411. (Pubitemid 24143442)
141. Yang, Y.; Li, Q.; Ertl, H. C.; Wilson, J. M. Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J. Virol. 1995, 69, 2004-2015.
142. Yang, Y.; Trinchieri, G.; Wilson, J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1995, 1, 890-893.
143. Alba, R.; Bosch, A.; Chillon, M. Gutless adenovirus: lastgeneration adenovirus for gene therapy. Gene Ther. 2005, 12 (Suppl. 1), S18-27. (Pubitemid 41541750)
144. Leen, A. M.; Christin, A.; Khalil, M.; Weiss, H.; Gee, A. P.; Brenner, M. K.; Heslop, H. E.; Rooney, C. M.; Bollard, C. M. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J. Virol. 2008, 82, 546-554. (Pubitemid 350309169)
145. Lamfers, M. L.; Fulci, G.; Gianni, D.; Tang, Y.; Kurozumi, K.; Kaur, B.; Moeniralm, S.; Saeki, Y.; Carette, J. E.; Weissleder, R.; Vandertop, W. P.; van Beusechem, V. W.; Dirven, C. M.; Chiocca, E. A. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. 2006, 14, 779-788. (Pubitemid 44743132)
146. Nokisalmi, P.; Pesonen, S.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Laasonen, L.; Partanen, K.; Alemany, R.; Rojas, J. J.; Guse, K.; Rajecki, M.; Kangasniemi, L.; Haavisto, E.; Karioja-Kallio, A.; Hannuksela, P.; Oksanen, M.; Kanerva, A.; Joensuu, T.; Ahtiainen, L.; Hemminki, A. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin. Cancer Res. 2010, 16, 3035-3043.
147. Cerullo, V.; Escutenaire, S.; Pesonen, S.; Diaconu, I.; Holm, S.- L.; Kanerva, A.; Kangasniemi, L.; Haavisto, E.; Oksanen, M.; Joensuu, T.; Karioja-Kallio, A.; Arstila, P.; Hemminki, A. Immunological effects of oral and intravenous cyclophosphamide in cancer patients treated with oncolytic adenoviruses. Mol. Ther. 2010, 18, 208.
148. Huebner, R. J.; Rowe, W. P.; Schatten, W. E.; Smith, R. R.; Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9, 1211-1218.
149. Rajecki, M.; Raki, M.; Escutenaire, S.; Pesonen, S.; Cerullo, V.; Helminen, A.; Hannuksela, P.; Partanen, K.; Laasonen, L.; Joensuu, T.; Kangasniemi, L.; Haavisto, E.; Kanerva, A.; Ahtiainen, L.; Hemminki, A. Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. Mol. Pharmaceutics 2010. DOI: 10.1021/mp1002174.
150. Toth, K.; Spencer, J. F.; Dhar, D.; Sagartz, J. E.; Buller, R. M.; Painter, G. R.; Wold, W. S. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 7293-7297. (Pubitemid 351754471)
151. Diaconu, I.; Cerullo, V.; Escutenaire, S.; Kanerva, A.; Bauerschmitz, G. J.; Hernandez-Alcoceba, R.; Pesonen, S.; Hemminki, A. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. J. Gene Med. 2010, 12, 435-445.
152. Reid, T.; Warren, R.; Kirn, D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002, 9, 979-986. (Pubitemid 35462561)
153. Varghese, R.; Mikyas, Y.; Stewart, P. L.; Ralston, R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J. Virol. 2004, 78, 12320-12332. (Pubitemid 39458751)
154. Cichon, G.; Boeckh-Herwig, S.; Schmidt, H. H.; Wehnes, E.; Muller, T.; Pring-Akerblom, P.; Burger, R. Complement activation by recombinant adenoviruses. Gene Ther. 2001, 8, 1794-1800. (Pubitemid 34100580)
155. Chen, Y.; Yu, D. C.; Charlton, D.; Henderson, D. R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. 2000, 11, 1553-1567. (Pubitemid 30670607)
156. Raki, M.; Diaconu, I.; Sarkioja, M.; Escutenaire, S.; Kangasniemi, L.; Kanerva, A.; Cerullo, V.; Joensuu, T.; Pesonen, S.; Hemminki, A. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. Mol. Ther. 2010, ASGCT Abstracts 2010.
157. Mastrangeli, A.; Harvey, B. G.; Yao, J.; Wolff, G.; Kovesdi, I.; Crystal, R. G.; Falck-Pedersen, E. "Sero-switch" adenovirusmediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 1996, 7, 79-87.
158. Kass-Eisler, A.; Leinwand, L.; Gall, J.; Bloom, B.; Falck-Pedersen, E. Circumventing the immune response to adenovirusmediated gene therapy. Gene Ther. 1996, 3, 154-162.
159. O'Riordan, C. R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S. C.; Smith, A. E.; Francis, G. E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10, 1349-1358. (Pubitemid 29267589)
160. Koski, A.; Pesonen, S.; Cerullo, V.; Escutenaire, S.; Nokisalmi, P.; Raki, M.; Rajecki, M.; Haavisto, E.; Guse, K.; Diaconu, I.; Oksanen, M.; Holm, S.-L.; Laasonen, L.; Partanen, K.; Ugolini, M.; Kangasniemi, L.; Helminen, A.; Karli, E.; Karioja-Kallio, A.; Joensuu, T.; Hemminki, A. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Hum. Gene Ther. 2009, 11, 1384.
161. Pesonen, S.; Cerullo, V.; Escutenaire, S.; Raki, M.; Kangasniemi, L.; Karli, E.; Haavisto, E.; Oksanen, M.; Joensuu, T.; Kanerva, A.; Hemminki, A. Treatment of cancer patients with integrintargeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGDD24- GMCSF. Mol. Ther. 2010, 18, 256.
162. Pesonen, S.; Nokisalmi, P.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Kangasniemi, L.; Laasonen, L.; Ribacka, C.; Guse, K.; Haavisto, E.; Oksanen, M.; Rajecki, M.; Helminen, A.; Ristimaki, A.; Karioja-Kallio, A.; Karli, E.; Kantola, T.; Bauerschmitz, G.; Kanerva, A.; Joensuu, T.; Hemminki, A. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 2010, 17, 892-904.
163. Escutenaire S.; Cerullo, V.; Diaconu, I.; Ahtiainen, L.; Hannuksela, P.; Oksanen, M.; Haavisto, E.; Karioja-Kallio, A.; Holm, S.-L.; Kangasniemi, L.; Ribacka, C.; Kauppinen, S.; Joensuu, T.; Arstila, P.; Pesonen, S.; Kanerva, A.; Hemminki, A. In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Ann. Med. 2010, in press.
164. Zhu, H.; Su, Y.; Zhou, S.; Xiao, W.; Ling, W.; Hu, B.; Liu, Y.; Qi, Y. Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice. Cancer Biol. Ther. 2007, 6, 724-731. (Pubitemid 47328354)
165. Shayakhmetov, D. M.; Li, Z. Y.; Ni, S.; Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 2004, 78, 5368-5381. (Pubitemid 38581487)
166. Tao, N.; Gao, G. P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J. M.; Barsoum, J.; Fawell, S. E. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 2001, 3, 28-35. (Pubitemid 32509802)
167. Connelly, S. Adenoviral vectors for liver-directed gene therapy. Curr. Opin. Mol. Ther. 1999, 1, 565-572. (Pubitemid 29522880)
168. Stone, D.; Liu, Y.; Shayakhmetov, D.; Li, Z. Y.; Ni, S.; Lieber, A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 2007, 81, 4866-4871. (Pubitemid 46668683)
169. Haisma, H. J.; Kamps, J. A.; Kamps, G. K.; Plantinga, J. A.; Rots, M. G.; Bellu, A. R. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J. Gen. Virol. 2008, 89, 1097-1105.
170. Collins, A. T.; Berry, P. A.; Hyde, C.; Stower, M. J.; Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951. (Pubitemid 41713363)
171. Szotek, P. P.; Pieretti-Vanmarcke, R.; Masiakos, P. T.; Dinulescu, D. M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; Maclaughlin, D. T.; Donahoe, P. K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11154-11159. (Pubitemid 44156488)
172. Ma, S.; Chan, K. W.; Hu, L.; Lee, T. K.; Wo, J. Y.; Ng, I. O.; Zheng, B. J.; Guan, X. Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132, 2542-2556. (Pubitemid 46890873)
173. Fang, D.; Nguyen, T. K.; Leishear, K.; Finko, R.; Kulp, A. N.; Hotz, S.; Van Belle, P. A.; Xu, X.; Elder, D. E.; Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65, 9328-9337. (Pubitemid 41508000)
174. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3983-3988. (Pubitemid 36418143)
175. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401. (Pubitemid 39551674)
176. Ribacka, C.; Hemminki, A. Virotherapy as an approach against cancer stem cells. Curr. Gene Ther. 2008, 8, 88-96.
177. Ribacka, C.; Pesonen, S.; Hemminki, A. Cancer, stem cells, and oncolytic viruses. Ann. Med. 2008, 40, 496-505.
178. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284. (Pubitemid 40488633)
179. Rich, J. N. Cancer stem cells in radiation resistance. Cancer Res. 2007, 67, 8980-8984. (Pubitemid 47535877)
180. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111. (Pubitemid 33041634)
181. Jordan, C. T.; Guzman, M. L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253-1261. (Pubitemid 44427449)
182. Coukos, G.; Makrigiannakis, A.; Kang, E. H.; Rubin, S. C.; Albelda, S. M.; Molnar-Kimber, K. L. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin. Cancer Res. 2000, 6, 3342-3353. (Pubitemid 30637766)
183. Mizuguchi, H.; Sasaki, T.; Kawabata, K.; Sakurai, F.; Hayakawa, T. Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2005, 332, 1101-1106. (Pubitemid 40798198)
184. Jiang, H.; Gomez-Manzano, C.; Aoki, H.; Alonso, M. M.; Kondo, S.; McCormick, F.; Xu, J.; Kondo, Y.; Bekele, B. N.; Colman, H.; Lang, F. F.; Fueyo, J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst. 2007, 99, 1410-1414. (Pubitemid 351767180)
185. Dmitriev, I.; Kashentseva, E.; Rogers, B. E.; Krasnykh, V.; Curiel, D. T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 2000, 74, 6875-6884. (Pubitemid 30470671)
186. Ganly, I.; Kirn, D.; Eckhardt, G.; Rodriguez, G. I.; Soutar, D. S.; Otto, R.; Robertson, A. G.; Park, O.; Gulley, M. L.; Heise, C.; Von Hoff, D. D.; Kaye, S. B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000, 6, 798-806. (Pubitemid 30159332)
187. Nemunaitis, J.; Ganly, I.; Khuri, F.; Arseneau, J.; Kuhn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD genedeleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000, 60, 6359-6366.
188. Ries, S.; Korn, W. M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 2002, 86, 5-11. (Pubitemid 34146332)
189. Crompton, A. M.; Kirn, D. H. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 2007, 7, 133-139. (Pubitemid 46348627)
190. Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Bruso, P.; Kaye, S. B.; Hong, W. K.; Kirn, D. H. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000, 6, 879-885. (Pubitemid 30644745)
191. DeWeese, T. L.; van der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; DeMarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61, 7464-7472. (Pubitemid 32995035)
192. Ramesh, N.; Ge, Y.; Ennist, D. L.; Zhu, M.; Mina, M.; Ganesh, S.; Reddy, P. S.; Yu, D. C. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 2006, 12, 305-313. (Pubitemid 43166208)
193. Cerullo, V.; Pesonen, S.; Diaconu, I.; Escutenaire, S.; Arstila, P. T.; Ugolini, M.; Nokisalmi, P.; Raki, M.; Laasonen, L.; Sarkioja, M.; Rajecki, M.; Kangasniemi, L.; Guse, K.; Helminen, A.; Ahtiainen, L.; Ristimaki, A.; Raisanen-Sokolowski, A.; Haavisto, E.; Oksanen, M.; Karli, E.; Karioja-Kallio, A.; Holm, S. L.; Kouri, M.; Joensuu, T.; Kanerva, A.; Hemminki, A. Oncolytic adenovirus coding for granulocyte macrophage colonystimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010, 70, 4297-4309.
194. Koski, A.; Kangasniemi, L.; Escutenaire, S.; Pesonen, S.; Cerullo, V.; Diaconu, I.; Nokisalmi, P.; Raki, M.; Rajecki, M.; Guse, K.; Ranki, T.; Oksanen, M.; Holm, S. L.; Haavisto, E.; Karioja- Kallio, A.; Laasonen, L.; Partanen, K.; Ugolini, M.; Helminen, A.; Karli, E.; Hannuksela, P.; Joensuu, T.; Kanerva, A.; Hemminki, A. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol. Ther. 2010, 18, 1874-1884.
195. Durrant, L. G.; Pudney, V.; Spendlove, I.; Metheringham, R. L. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opin. Biol. Ther. 2010, 10, 735-748.
196. Dias, J. D.; Guse, K.; Nokisalmi, P.; Eriksson, M.; Chen, D. T.; Diaconu, I.; Tenhunen, M.; Liikanen, I.; Grenman, R.; Savontaus, M.; Pesonen, S.; Cerullo, V.; Hemminki, A. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur. J. Cancer 2010, 46, 625-635.
197. Raki, M.; Kanerva, A.; Ristimaki, A.; Desmond, R. A.; Chen, D. T.; Ranki, T.; Sarkioja, M.; Kangasniemi, L.; Hemminki, A. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 2005, 12, 1198-1205. (Pubitemid 41136314)
198. Rajecki, M.; af Hallstrom, T.; Hakkarainen, T.; Nokisalmi, P.; Hautaniemi, S.; Nieminen, A. I.; Tenhunen, M.; Rantanen, V.; Desmond, R. A.; Chen, D. T.; Guse, K.; Stenman, U. H.; Gargini, R.; Kapanen, M.; Klefstrom, J.; Kanerva, A.; Pesonen, S.; Ahtiainen, L.; Hemminki, A. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int. J. Cancer 2009, 125, 2441-2449.
199. Pages, F.; Galon, J.; Dieu-Nosjean, M. C.; Tartour, E.; Sautes- Fridman, C.; Fridman, W. H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2009, 29, 1093-1102.
200. De Roock, W.; Biesmans, B.; De Schutter, J.; Tejpar, S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol. Diagn. Ther. 2009, 13, 103-114.
201. Mulvihill, S.; Warren, R.; Venook, A.; Adler, A.; Randlev, B.; Heise, C.; Kirn, D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 2001, 8, 308-315. (Pubitemid 32237064)
202. Nemunaitis, J.; Cunningham, C.; Buchanan, A.; Blackburn, A.; Edelman, G.; Maples, P.; Netto, G.; Tong, A.; Randlev, B.; Olson, S.; Kirn, D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001, 8, 746-759. (Pubitemid 32509788)
203. Vasey, P. A.; Shulman, L. N.; Campos, S.; Davis, J.; Gore, M.; Johnston, S.; Kirn, D. H.; O'Neill, V.; Siddiqui, N.; Seiden, M. V.; Kaye, S. B. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 2002, 20, 1562-1569. (Pubitemid 34260536)
204. Habib, N.; Salama, H.; Abd El Latif Abu Median, A.; Isac Anis, I.; Abd Al Aziz, R. A.; Sarraf, C.; Mitry, R.; Havlik, R.; Seth, P.; Hartwigsen, J.; Bhushan, R.; Nicholls, J.; Jensen, S. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002, 9, 254-259. (Pubitemid 34205499)
205. Chiocca, E. A.; Abbed, K. M.; Tatter, S.; Louis, D. N.; Hochberg, F. H.; Barker, F.; Kracher, J.; Grossman, S. A.; Fisher, J. D.; Carson, K.; Rosenblum, M.; Mikkelsen, T.; Olson, J.; Markert, J.; Rosenfeld, S.; Nabors, L. B.; Brem, S.; Phuphanich, S.; Freeman, S.; Kaplan, R.; Zwiebel, J. A phase I open-label, doseescalation, multi-institutional trial of injection with an E1BAttenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 2004, 10, 958-966. (Pubitemid 39419921)
206. Nemunaitis, J.; Senzer, N.; Sarmiento, S.; Zhang, Y. A.; Arzaga, R.; Sands, B.; Maples, P.; Tong, A. W. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther. 2007, 14, 885-893. (Pubitemid 47557221)
207. Habib, N. A.; Sarraf, C. E.; Mitry, R. R.; Havlik, R.; Nicholls, J.; Kelly, M.; Vernon, C. C.; Gueret-Wardle, D.; El-Masry, R.; Salama, H.; Ahmed, R.; Michail, N.; Edward, E.; Jensen, S. L. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 2001, 12, 219-226. (Pubitemid 32163894)
208. Reid, T. R.; Freeman, S.; Post, L.; McCormick, F.; Sze, D. Y. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005, 12, 673-681. (Pubitemid 41045565)
209. Nemunaitis, J.; Khuri, F.; Ganly, I.; Arseneau, J.; Posner, M.; Vokes, E.; Kuhn, J.; McCarty, T.; Landers, S.; Blackburn, A.; Romel, L.; Randlev, B.; Kaye, S.; Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 2001, 19, 289-298. (Pubitemid 32112839)
210. Hecht, J. R.; Bedford, R.; Abbruzzese, J. L.; Lahoti, S.; Reid, T. R.; Soetikno, R. M.; Kirn, D. H.; Freeman, S. M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9, 555-561. (Pubitemid 36182584)
211. Hamid, O.; Varterasian, M. L.; Wadler, S.; Hecht, J. R.; Benson, A., 3rd; Galanis, E.; Uprichard, M.; Omer, C.; Bycott, P.; Hackman, R. C.; Shields, A. F. Phase II trial of intravenous CI- 1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 1498-1504. (Pubitemid 46594102)
212. Xia, Z. J.; Chang, J. H.; Zhang, L.; Jiang, W. Q.; Guan, Z. Z.; Liu, J. W.; Zhang, Y.; Hu, X. H.; Wu, G. H.; Wang, H. Q.; Chen, Z. C.; Chen, J. C.; Zhou, Q. H.; Lu, J. W.; Fan, Q. X.; Huang, J. J.; Zheng, X. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Aizheng 2004, 23, 1666-1670.
213. Galanis, E.; Okuno, S. H.; Nascimento, A. G.; Lewis, B. D.; Lee, R. A.; Oliveira, A. M.; Sloan, J. A.; Atherton, P.; Edmonson, J. H.; Erlichman, C.; Randlev, B.; Wang, Q.; Freeman, S.; Rubin, J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005, 12, 437-445. (Pubitemid 40394296)
214. Freytag, S. O.; Movsas, B.; Aref, I.; Stricker, H.; Peabody, J.; Pegg, J.; Zhang, Y.; Barton, K. N.; Brown, S. L.; Lu, M.; Savera, A.; Kim, J. H. Phase I trial of replication-competent adenovirusmediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 2007, 15, 1016-1023. (Pubitemid 46621661)
215. Li, J. L.; Liu, H. L.; Zhang, X. R.; Xu, J. P.; Hu, W. K.; Liang, M.; Chen, S. Y.; Hu, F.; Chu, D. T. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009, 16, 376-382.